CLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CLX is not a good buy right now for a beginner, long-term investor with $50,000-$100,000 who wants a straightforward entry and is impatient about waiting. The stock has a defensive/dividend profile, but the current setup is not strong enough to justify a fresh buy: trend is still weak, analysts are mostly cautious to bearish, and insiders/hedge funds are neutral. The best call here is hold and wait rather than buy aggressively now.
Current price is 95.82, slightly above the 95.27 reference price and near pivot support at 95.10. However, the broader trend is still weak: MACD histogram is negative, RSI_6 is neutral at 52.86, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. That structure suggests the stock is still in a longer-term downtrend or consolidation under pressure. Short-term support sits at 91.67, while resistance is 98.53 and then 100.65. The stock trend model suggests near-term upside potential, but the chart setup is not a clean bullish breakout.
["Defensive consumer-staples business can appeal to long-term dividend-focused investors.", "News mentions Clorox's $2.25 billion GOJO acquisition, which could support hand-hygiene sales growth over time.", "Options sentiment is mildly positive with put-call ratios below 1.0.", "The stock has a relatively stable profile compared with more cyclical names."]
["Analyst sentiment is weak overall, with several target cuts and multiple Sell/Underweight/Underperform ratings.", "Recent commentary points to weaker FY26 guidance, soft consumer and scanner trends, and ongoing cost pressures.", "Technical trend remains bearish with SMA_200 above shorter averages and negative MACD.", "Congress trading data shows 2 sale transactions and 0 purchases, indicating caution.", "Hedge funds and insiders are neutral, showing no notable accumulation."]
No usable financial snapshot was provided due to an error, so there is no valid quarter-by-quarter financial table to assess. Based on the analyst commentary, the latest quarter appears to have included a slight EPS beat in Q3, but the company also issued weaker FY26 guidance and described ongoing pressure from costs, consumer softness, ERP transition impacts, and acquisition-related integration challenges. The latest quarter season referenced in the analyst notes is Q3.
Wall Street pros are mostly negative to cautious. Goldman Sachs kept Sell and cut target to 83, Barclays kept Underweight and cut to 85, JPMorgan kept Underweight and cut to 95, Evercore kept Underperform, and Deutsche Bank kept Hold with a cut to 91. Morgan Stanley, UBS, and Citi are Neutral/Equal Weight but also reduced targets. Jefferies is the main positive outlier with a Buy rating, though it still lowered its target to 139 and noted a difficult outlook. Overall, the direction of analyst ratings and price targets is downward, and the pro consensus leans cautious-to-bearish.
